eduKate Learning Manual
Science | Veterinary World
Describe the Lymphoid Population → Preserve Morphology → Define Immunophenotype → Test Antigen-Receptor Rearrangement → Distinguish Clonal From Polyclonal Signal → Check Assay and Sample Limits → Integrate the Whole Disease

Veterinary PARR Clonality Testing

Why a Clonal Lymphocyte Population Does Not Automatically Prove Lymphoma

Wait, What? A Molecular Test Can Show That Many Lymphocytes Share the Same Rearrangement Without Proving That the Population Is Malignant

Normal B and T lymphocytes rearrange antigen-receptor genes as they mature. That process gives each clone a distinctive sequence. In a healthy reactive immune response, many different lymphocyte clones usually contribute, producing a broad or polyclonal molecular pattern. In many lymphomas, one neoplastic clone dominates, creating a restricted or clonal pattern.

That makes PCR for antigen receptor rearrangement—PARR—extremely useful. But clonality and cancer are not synonyms. Strong antigenic stimulation can expand a limited number of normal clones. Some lymphomas fail to produce a detectable clonal result because primer sets do not match the rearrangement, the neoplastic population is too small, DNA quality is poor or the tumour falls outside the assay’s best-performing biology.

clonal lymphocyte signal ≠ lymphoma proven; polyclonal signal ≠ lymphoma excluded.

The Scientific Job

This page owns one Veterinary World job:

How should veterinarians interpret PARR as molecular evidence of lymphocyte-population restriction without allowing clonality to replace cytology, histopathology, immunophenotyping or clinical context?

Veterinary Flow Cytometry retains cell-population immunophenotyping. Veterinary Lymph Node Cytology retains cell morphology. Veterinary Cytology vs Histopathology retains tissue-architecture boundaries. This page owns the narrower molecular question of lymphocyte clonality.

Quick Answer

PARR amplifies rearranged immunoglobulin or T-cell receptor gene regions to determine whether a lymphocyte population is molecularly diverse or dominated by one rearrangement. A clonal result supports a restricted lymphoid population and can strengthen suspicion of lymphoma or leukaemia when morphology and immunophenotype agree. It should not be used as a stand-alone malignancy test or in place of immunophenotyping.

A veterinary diagnostic review specifically recommends clonality testing as an adjunct that follows clinical, morphological and immunophenotypic assessment. The 2025 Oncology-Pathology Working Group consensus on canine nodal lymphoma states that molecular clonality testing should not replace immunophenotyping and that complete nodal lymphoma classification requires histopathology with immunohistochemistry.

Explore Veterinary Pathology — Clonality Testing Review and Diagnostic Guidelines →

Explore 2025 OPWG Consensus — Canine Nodal Lymphoma Diagnosis and Classification →

Primary Entry — Why Normal Lymphocytes Rearrange Their DNA

B and T lymphocytes need enormous receptor diversity. During development, antigen-receptor gene segments are rearranged so that different lymphocytes carry different receptor sequences.

A normal reactive population therefore tends to contain many rearrangements. A neoplastic lymphoid population often descends from one transformed cell, so its descendants inherit the same rearrangement.

many immune clones → broad molecular diversity; one expanding clone → restricted molecular pattern.

Part 1 — PARR Measures Population Structure, Not Cellular Appearance

PARR does not examine nuclear size, chromatin, mitoses, tissue architecture or antigen expression. It asks whether amplified antigen-receptor rearrangements form a broadly diverse pattern or a restricted one.

That means PARR can add information when cytology is ambiguous, when only a small sample is available, or when a lymphoid infiltrate is difficult to classify. It cannot replace the information that morphology and architecture provide.

Part 2 — Clonality Is Not the Same as Malignancy

Powerful immune stimulation can selectively expand one or a few lymphocyte clones. In such cases, a reactive process can appear oligoclonal or even strongly restricted.

This is one reason molecular clonality must remain linked to the tissue and disease story. A restricted molecular signal in a severely inflamed tissue is not equivalent to the same signal in a lymph node effaced by a monomorphic malignant population.

Part 3 — A Negative PARR Can Miss True Lymphoma

PARR depends on primers binding the rearranged receptor sequence. If the primer set does not adequately cover that rearrangement, amplification can fail.

Assay sensitivity also depends on how many neoplastic cells are present, DNA quality, sample type and the antigen-receptor locus being tested. A review of canine B-cell clonality assays showed meaningful variability in primer performance and supported continuing harmonisation and optimisation.

Explore Canine B-Cell Clonality Assays and Primer Optimisation →

Part 4 — Sample Type Changes Performance

Fresh aspirates, formalin-fixed paraffin-embedded tissue, flow-cytometry pellets, blood and body-cavity fluids contain different amounts and qualities of lymphoid DNA.

Benchmarking work in dogs found that PARR performance varied by sample type and by whether the assay was being used to distinguish lymphoma from non-lymphoma or to assign lineage. The practical lesson is that a PARR result belongs to the sample and assay that generated it.

Explore Benchmarking of Canine PARR Across Sample Types →

Part 5 — Lineage and Clonality Are Separate Questions

Flow cytometry or immunohistochemistry can identify B-cell or T-cell phenotype. PARR can sometimes suggest which antigen-receptor locus is clonally rearranged. But the two tasks are not interchangeable.

The 2025 OPWG consensus explicitly recommends immunohistochemistry or flow cytometry for reliable immunophenotyping and states that molecular clonality should not be used in place of those assays for lymphoma classification.

Secondary Deepening — Why Polyclonal Does Not Mean “Normal”

A severely inflamed lymph node can be polyclonal because many immune clones are activated. A lymphoma sample can also appear polyclonal if reactive lymphocytes outnumber the neoplastic clone or if the tumour rearrangement is not detected.

Therefore polyclonality is evidence of molecular diversity, not a universal certificate of benign disease.

Part 6 — Oligoclonality Lives Between the Textbook Extremes

Some samples show several dominant peaks rather than one or many. This oligoclonal pattern can occur during restricted immune responses, early neoplastic evolution or mixtures of reactive and neoplastic cells.

The correct response is not to force the pattern into “positive” or “negative”. It is to ask whether the rest of the disease evidence supports a clonal neoplasm.

Part 7 — Pseudoclonality Can Arise From Very Small Samples

If only a few lymphocytes contribute DNA, random over-representation of one rearrangement can mimic clonality. This is especially important in low-cellularity or heavily diluted samples.

Repeating amplification, reviewing DNA quantity and preserving morphology can help identify such artefacts.

Part 8 — Plasma-Cell Tumours Show Why Assay Design Matters

A 2025 canine study found that an extended PARR assay targeting multiple immunoglobulin loci detected clonality in more plasma-cell tumours than a routine IGH-focused assay. The biological disease had not changed; the assay’s genomic coverage had.

Explore 2025 PARR Sensitivity in Canine Plasma-Cell Tumours →

JC Deepening — Clonality Is a Probability Update, Not a Verdict

Imagine a lymph node whose cytology is strongly monomorphic and whose flow cytometry shows an aberrant B-cell population. A matching clonal PARR result adds independent molecular support.

Now imagine a chronically inflamed tissue with mixed lymphocytes and no aberrant phenotype. The same restricted molecular signal has a different meaning because the prior probability and competing explanations differ.

molecular pattern × morphology × immunophenotype × tissue context = stronger interpretation.

Part 9 — PARR Can Track a Known Clone Across Sites

Once a neoplastic clone has been characterised, matching rearrangements in another site can support dissemination of the same lymphoid population.

However, molecular detection of rare clonal cells does not automatically define clinical stage severity or prognosis. Earlier canine work found PARR more sensitive than visual assessment for circulating tumour cells but did not show that molecular stage alone predicted survival.

Explore PARR for Molecular Staging in Canine Lymphoma →

Part 10 — Discordance Is Information

When cytology, flow cytometry and PARR disagree, the temptation is to decide which test “won”. A better approach is to ask why they disagree.

Possibilities include poor DNA, low tumour fraction, unusual antigen expression, reactive clonal expansion, sampling of different regions or a disease whose biology sits near assay limits.

Part 11 — Recent Feline Evidence Reinforces the Negative-Test Boundary

A 2026 feline lymphoma report described cytologically convincing lymphoma in gastrointestinal and testicular sites despite absence of monoclonal rearrangements on PARR. One case cannot define universal sensitivity, but it illustrates the long-recognised principle that lack of detected clonality cannot conclusively exclude lymphoma.

Explore 2026 Feline Lymphoma Case — Diagnostic Limits of PARR →

Part 12 — Complete Nodal Lymphoma Classification Still Belongs to Tissue Pathology

For primary canine nodal lymphoma, the 2025 OPWG consensus places complete diagnosis and classification with histopathology plus immunohistochemistry. PARR is an important adjunct, particularly when samples are limited or results are ambiguous, but it does not recover tissue architecture.

How Do We Know?

The evidence base includes diagnostic guidelines, large canine validation studies, sample-type benchmarking, primer-optimisation research and the 2025 OPWG lymphoma consensus. Across those sources, the same boundary is consistent: PARR is valuable molecular evidence of population restriction, but neither a clonal nor a polyclonal result should be interpreted outside morphology, immunophenotype and clinical context.

Observation vs Inference

• Observation: cytology is monomorphic, flow cytometry shows an aberrant B-cell population and PARR is clonal.
• Inference: B-cell lymphoma is strongly supported.
• Observation: chronically inflamed tissue shows a restricted PARR pattern but mixed morphology.
• Inference: clonality is present; malignancy is not proven.
• Observation: suspicious lymphoma cytology has a polyclonal PARR result.
• Inference: assay sensitivity, tumour fraction and primer coverage must be considered; lymphoma remains possible.
• Observation: matching clonal rearrangement appears in two sites.
• Inference: dissemination of the same lymphoid clone becomes more plausible.

Evidence Boundaries

• clonal PARR ≠ lymphoma proven automatically.
• polyclonal PARR ≠ lymphoma excluded.
• clonality ≠ immunophenotype.
• PARR ≠ tissue architecture.
• one primer panel ≠ universal genomic coverage.
• small-sample restriction ≠ true biological clone automatically.
• matching clone across sites ≠ prognosis determined.
• molecular result ≠ treatment instruction.

Common Misconceptions

Misconception	Better model
Clonal means cancer.	Clonality supports restricted population structure; reactive clones can occur.
Polyclonal means benign.	False-negative lymphoma can occur because of assay and sampling limits.
PARR tells B-cell versus T-cell better than flow cytometry.	Immunophenotyping remains the preferred lineage-classification job.
Molecular testing makes histopathology unnecessary.	Architecture and morphology remain essential for complete nodal lymphoma classification.

Unfamiliar Transfer

Dog A has clonal PARR plus malignant cytology and aberrant flow cytometry. Dog B has clonal PARR in a severely inflamed intestine but mixed lymphocytes. Dog C has classic lymphoma morphology but polyclonal PARR from a low-cellularity sample. Cat D has the same clone detected in an enlarged node and peripheral blood.

A strong learner does not ask whether PARR is “positive”. The learner asks what molecular population structure was observed and whether independent evidence agrees with the same disease model.

Checkpoint Questions

1. Why do normal lymphocytes have unique antigen-receptor rearrangements?
2. What does a clonal PARR result physically mean?
3. Why can reactive disease sometimes look clonal?
4. Why can lymphoma sometimes look polyclonal?
5. How does sample type affect PARR?
6. Why should PARR not replace immunophenotyping?
7. What is pseudoclonality?
8. Why can an extended primer panel increase sensitivity?
9. How can PARR help with disease distribution?
10. Why does complete nodal classification still require tissue pathology?

Answer key

1. V(D)J rearrangement creates receptor diversity during lymphocyte development.
2. A restricted antigen-receptor rearrangement dominates the tested population.
3. Strong antigenic stimulation can expand one or a few normal clones.
4. Primer mismatch, low tumour fraction, DNA quality or sampling can reduce detection.
5. DNA quantity, preservation and tumour fraction vary by specimen.
6. Lineage phenotype and molecular population restriction are different questions.
7. Artificial apparent clonality caused by very few template lymphocytes.
8. It covers more possible rearrangements.
9. A matching known clone in another site can support dissemination.
10. PARR does not preserve architecture or full morphological classification.

Edge Science — Can Sequencing-Based Clonality Replace Peak Patterns?

High-throughput sequencing can identify exact antigen-receptor sequences rather than simply classifying an electrophoretic pattern as clonal or polyclonal. This may improve sensitivity, reveal minor subclones and allow precise tracking over time.

The deeper challenge remains unchanged: sequence restriction is not equivalent to malignant behaviour. Better molecular resolution increases the need for stronger biological interpretation, not less.

Veterinary World Direction Graph

Veterinary PARR clonality → suspicious lymphoid population → morphology → immunophenotype → DNA/sample quality → antigen-receptor amplification → clonal/polyclonal/oligoclonal pattern → assay limitation check → tissue/clinical integration → serial or cross-site comparison.

Research Sources and Further Reading

• Clonality Testing in Veterinary Medicine: Review With Diagnostic Guidelines
• 2025 OPWG Consensus — Diagnosis and Classification of Primary Nodal Lymphomas in Dogs
• Benchmarking PARR Performance Across Canine Sample Types
• 2025 PARR Sensitivity in Canine Plasma-Cell Tumours

Educational boundary: Suspected lymphoma, leukaemia or plasma-cell neoplasia requires veterinary and pathology assessment. This manual explains molecular clonality interpretation only and does not provide chemotherapy, prognosis for an individual animal or treatment instructions.

Teaching Guide for Parents, Tutors and Teachers

For the people who teach because somebody depends on them.

Imagine a stadium. If thousands of people are all singing different songs, the crowd is diverse. If almost everyone is singing the same song, one organised group may dominate. But the song alone does not tell you whether the group is dangerous, harmless or simply responding to the same event.

describe the cells → identify phenotype → measure clonality → check assay limits → return the molecular result to the tissue.

The mastery target is a learner who understands that molecular sameness is a powerful clue about population history, not an automatic diagnosis of malignancy.